Skip Navigation Links

Merck | Company Structure Information from ICIS

 

Merck is a global health care provider with a portfolio of prescription medicines, vaccines and animal and consumer health products.

 

Merck's product line includes a broad portfolio of prescription products in important therapeutic areas. Human health products include medicines to help treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hyperplasia, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, emesis, antibiotic, antifungal and antiviral agents, and vaccines to help prevent childhood diseases, pneumonia and hepatitis A and B.

 

The new Merck's portfolio also includes leading products from its Animal Health and Consumer Health Care business units.

 

Since its merger with Schering-Plough, Merck has approximately 94,000 employees and operates in more than 140 countries around the world, including emerging markets.

 

Its corporate headquarters are in Whitehouse Station, New Jersey, US.

 

Merck has five primary divisions: Global Human Health, Animal Health, Consumer Health Care, Merck Research Laboratories and Merck Manufacturing.

 

Download the The ICIS Top 100 Chemical Companies listing here

 

Merck and Schering-Plough merger

 

In November 2009, Merck & Co and Schering-Plough completed its planned merger. The merged companies will operate under the Merck name.

 

“With our merger now complete, we are ready to deliver on the promise of a new Merck built on a foundation of scientific innovation and dedication to the well-being of patients around the world,” said chairman, president and chief executive officer, Richard Clark.

 

In October 2009, Merck & Co and Schering-Plough received clearance from the European Commission (EC) under the EC Merger Regulation for its proposed merger.

 

Also in October 2009, Merck & Co and Schering-Plough received clearance from US Federal Trade Commission (FTC), the Swiss Competition Commission and the Canadian Competition Bureau for its proposed merger.  

 

In August 2009, Schering-Plough approved the merger with Merck & Co.

 

The merger was first announced in March 2009.

 

Company movements

 

In March 2010, Sanofi-aventis and Merck & Co said that Sanofi-aventis had exercised its option to combine Merial with Intervet/Schering-Plough, Merck’s Animal Health business.

The new joint venture will be equally-owned by Merck and Sanofi-aventis and is subject to execution of final agreements, antitrust review in the US, Europe and other countries and other customary closing conditions. The completion of the transaction is expected to occur within a year.

Merck Strategy & Financial Highlights

In August 2009, Schering-Plough approved the merger with Merck & Co. It is believed that by combining the two companies it will create a “strong global health care leader”. Under the name “Merck”, the combined company will be headed by Merck chairman, president and chief executive officer, Richard Clark and have headquarters in Whitehouse Station, New Jersey, US. More about Merck Strategy & Financial Highlights

News:

Get news on Merck plus the latest chemical news, information, data, market movements and analysis in one place with ICIS news

Search:

Find details on other chemical companies and suppliers with ICIS search

Newsletters:

ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.

Plants and projects:

Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database

 
Free trial to ICIS
ICIS Chemical Business - ICIS Chemical Business Editor’s Comment
This blog records content for the Editor’s comment of ICIS Chemical Business ahead of publication. It is a series of works in progress. To read the definitive version of the column subscribe to ICIS Chemical Business on paper and on line.

Insight

INSIGHT: Counting the cost of the shift to liquids for GCC chemicals
"The degree of sophistication required to do this successfully is immense." more

VIDEO: ICIS special report - impact of lower crude oil prices

More...

We welcome your feedback. Please feel free to send us your comments on any aspect of this site. Click here to make your comments.